Tarsus Pharmaceuticals, Inc.
TARS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001819790
In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Tarsus Pharmaceuticals, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 205 | 1 | 220 | +16 |
| Shares | 46.1M | 471.4K | 44.9M | −766.1K (−1.7%) |
| Value | $1.87B | $19.1M | $2.67B | +$818.1M (+44.2%) |
1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (37)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (21)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Adage Capital Partners GP, L.L.C. | 543,000 | $22.0M |
| Balyasny Asset Management LLC | 138,019 | $5.59M |
| Gilder Gagnon Howe & Co LLC | 77,164 | $3.13M |
| Susquehanna International Group, LLP | 52,334 | $2.12M |
| Aquatic Capital Management LLC | 36,354 | $1.47M |
| Schonfeld Strategic Advisors LLC | 32,411 | $1.31M |
| Graham Capital Management, L.P. | 24,774 | $1.00M |
| Magnetar Financial LLC | 14,721 | $596.3K |
| Quadrature Capital Ltd | 14,500 | $588.4K |
| Warren Averett Asset Management, LLC | 13,197 | $534.6K |
| Occudo Quantitative Strategies LP | 11,905 | $482.3K |
| UBS Oconnor LLC | 11,000 | $445.6K |
| Bridgefront Capital, LLC | 10,729 | $434.6K |
| Versor Investments LP | 9,492 | $384.5K |
| Petrus Trust Company, LTA | 7,061 | $286.0K |
| State of Wyoming | 363 | $14.7K |
| Caitong International Asset Management Co., Ltd | 139 | $5.63K |
| Accent Capital Management, LLC | 105 | $4.25K |
| Signaturefd, LLC | 23 | $932 |
| Geneos Wealth Management Inc. | 23 | $932 |
| Twin Peaks Wealth Advisors, LLC | 1 | $51 |
Not filed for Q3 2025 yet (1)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Norges Bank | 471,354 | $19.1M |